Organon Has Expanded Its Agreement With Eli Lilly To Become The Sole Distributor And Promoter Of The Migraine Medicine Emgality (Galcanezumab) In Additional Markets, Total Consideration To Be Paid To Lilly Includes An Upfront Payment Of $22.5M As Well As Sales-based Milestone Payments
Portfolio Pulse from Benzinga Newsdesk
Organon has expanded its agreement with Eli Lilly to become the sole distributor and promoter of the migraine medicine Emgality in additional markets. The deal includes an upfront payment of $22.5 million to Lilly and sales-based milestone payments.
August 20, 2024 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly will receive $22.5 million upfront and sales-based milestone payments from Organon for expanding the distribution of Emgality.
Eli Lilly benefits financially from the expanded agreement with Organon through an upfront payment and potential milestone payments, which could positively impact its revenue.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Organon has secured an expanded agreement with Eli Lilly to distribute and promote Emgality, potentially boosting its market presence and revenue.
The expanded agreement allows Organon to distribute and promote Emgality in additional markets, which could lead to increased sales and revenue. The upfront payment and milestone payments indicate a significant investment in this partnership.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80